lassomycin

a ribosomally synthesized peptide that kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2; amino acid sequence in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Brimble, Margaret A: 1 article (01/2021)
2.	Hanna, Cameron C: 1 article (01/2021)
3.	Harris, Paul W R: 1 article (01/2021)
4.	Hermant, Yann O: 1 article (01/2021)
5.	Feng, Yue: 1 article (05/2019)
6.	Shams, Saira: 1 article (05/2019)
7.	Su, Yu: 1 article (05/2019)
8.	Tong, Yigang: 1 article (05/2019)
9.	Zheng, Guojun: 1 article (05/2019)
10.	Zhu, Shaozhou: 1 article (05/2019)

Related Diseases

1.	Tuberculosis (Tuberculoses) 05/01/2019 - "Among all the reported lasso peptides, lassomycin and lariatins are unique lasso peptides that exhibit noticeable anti-tuberculosis (TB) activity. " 01/01/2019 - "ClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. "
2.	Infections 05/01/2019 - "Lassomycin and lariatin lasso peptides as suitable antibiotics for combating mycobacterial infections: current state of biosynthesis and perspectives for production." 01/01/2021 - " mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A. "

Related Drugs and Biologics

1.	Cyclic Peptides
2.	Peptides (Polypeptides)
3.	Anti-Bacterial Agents (Antibiotics)
4.	trichoderin A
5.	cyclomarin A
6.	callyaerin A
7.	ecumicin
8.	teixobactin